Progyny, Inc. announced the launch of Progyny Select, the industry’s first fully insured supplemental fertility and family‑building plan designed for small employers. The new product bundles Progyny’s managed provider network, Smart Cycle benefit design, and personalized member navigation into a single, fully insured offering with fixed per‑employee‑per‑month pricing.
Progyny Select covers a broad range of services, including in‑vitro fertilization, intrauterine insemination, genetic testing, and support for adoption, surrogacy, pregnancy, postpartum, parenting, and menopause. The fixed‑premium model provides predictable costs for employers while the pooled‑risk structure limits the company’s exposure to high‑cost claims.
The plan is being distributed through brokers, health‑plan partners, and general agents such as Emerson Rogers, and will be available for implementation in employer 2027 plan years. This distribution strategy leverages existing relationships in the fragmented small‑employer market to accelerate adoption.
Strategically, Progyny Select expands the company’s reach beyond its traditional large‑employer customer base to approximately 50 million U.S. workers in small businesses. By offering a fully insured, pooled‑risk model, Progyny aims to make fertility and women’s health benefits a standard of care for employers of all sizes, potentially driving new client acquisition and deepening existing relationships.
The fixed‑premium, fully insured structure provides Progyny with predictable revenue streams and reduces cost uncertainty, while the pooled‑risk approach limits exposure to high‑cost claims. Management has emphasized that access to fertility benefits should not depend on employer size, underscoring the company’s commitment to expanding inclusive benefits.
The U.S. fertility market is large and growing, with 42% of employers now offering fertility benefits and a projected $39 billion addressable market. Small employers have historically faced barriers to comprehensive fertility coverage; Progyny Select directly addresses that gap, strengthening Progyny’s competitive position and positioning the company for broader market penetration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.